Exploration of structure-activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis

Peptides

Volumn 31, Issue 7, 2010, Pages 1353-1360

  Haque, Tasir S ^a   Martinez, Rogelio L ^a   Lee, Ving G ^a   Riexinger, Douglas G ^a   Lei, Ming ^a   Feng, Ming ^a   Koplowitz, Barry ^a   Mapelli, Claudio ^a   Cooper, Christopher B ^a   Zhang, Ge ^a   Huang, Christine ^a   Ewing, William R ^a   Krupinski, John ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

11mer; Agonist; Biphenylalanine; Combinatorial; GLP 1R; Library; Parallel

Indexed keywords

AMINO ACID DERIVATIVE; BIPHENYLALANINE; DIPEPTIDE DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; RECEPTORS, GLUCAGON; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952543363     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.04.013     Document Type: Article

References (16)

1. Agerso H., Jensen L.B., Elbrond B., Rolan P., and Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new, long-acting GLP-1 derivative, in healthy men. Diabetologia 45 2 (2002) 195-202
2. Barlos K., and Gatos D. 9-Fluorenylmethoxycarbonyl/t-butyl-based convergent protein synthesis. Biopolymers 51 4 (1999) 266-278
3. Bell G.I., Sanchez-Pescador R., Laybourn P.J., and Najarian R.C. Exon duplication and divergence in the human preproglucagon gene. Nature 304 5924 (1983) 368-371
4. Bell G.I., Santerre R.F., and Mullenback G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302 5910 (1983) 716
5. Centers for Disease Control and Prevention. "National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005." Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005. Available on the worldwide web at http://www.cdc.gov/diabetes/pubs/factsheet05.htm.
6. Drucker D.J., and Nauck M.A. The incretin system: Glucagon-Like Peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 9658 (2006) 1696-1705
7. Haque T.S., Ruan Z., Lee V.G., Riexinger D.G., Lei M., Malmstrom S., et al. Identification of potent 11mer Glucagon-Like Peptide-1 agonist peptides with novel C-terminal amino acids. Homohomophenylalanine analogues. Peptides 31 5 (2010) 950-955
8. Hoare S.R.J. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10 6 (2005) 417-427
9. Lenhard J.M., and Gottschalk W.K. Preclinical developments in type 2 diabetes. Adv Drug Deliv Rev 54 (2002) 1199-1212
10. Lovshin J.A., and Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5 5 (2009) 262-269
11. Mapelli C., Natarajan S., Meyer J.-P., Bastos M., Bernatowicz M., Lee V., et al. Eleven amino acid Glucagon-Like Peptide-1 receptor agonists with antidiabetic activity. J Med Chem 52 23 (2009) 7788-7799
12. Miyaura N., Yamada K., and Suzuki A. A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides. Tetrahedron Lett 20 36 (1979) 3437-3440
13. Nielsen L.L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10 10 (2005) 703-710
14. Perry T., and Greig N.H. The Glucagon-Like Peptides: a double-edged therapeutic sword?. Trends Pharmacol Sci 24 7 (2003) 377-383
15. Roges O.A., Baron M., and Philis-Tsimikas A. The incretin effect and its potentiation by Glucagon-Like Peptide 1-based therapies: a revolution in diabetes management. Expert Opin Investig Drugs 14 6 (2005) 705-727
16. Trivedi H.S., Anson M., Steel P.G., and Worley J. A method for selective N-Boc deprotection on Wang resin. Synlett (2001) 1932-1934